Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 3
1966 1
1973 3
1975 1
1978 2
1980 2
1981 2
1982 6
1983 1
1984 2
1985 1
1986 3
1987 2
1988 3
1989 7
1990 4
1991 1
1993 1
1994 3
1996 3
1997 4
1998 2
1999 5
2000 10
2001 8
2002 11
2003 6
2004 11
2005 12
2006 15
2007 16
2008 21
2009 21
2010 17
2011 23
2012 23
2013 26
2014 32
2015 37
2016 36
2017 42
2018 30
2019 27
2020 31
2021 34
2022 28
2023 28
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

520 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.
IL-25 enhances TH17 cell-mediated contact dermatitis by promoting IL-1β production by dermal dendritic cells.
Suto H, Nambu A, Morita H, Yamaguchi S, Numata T, Yoshizaki T, Shimura E, Arae K, Asada Y, Motomura K, Kaneko M, Abe T, Matsuda A, Iwakura Y, Okumura K, Saito H, Matsumoto K, Sudo K, Nakae S. Suto H, et al. Among authors: yoshizaki t. J Allergy Clin Immunol. 2018 Nov;142(5):1500-1509.e10. doi: 10.1016/j.jaci.2017.12.1007. Epub 2018 Mar 6. J Allergy Clin Immunol. 2018. PMID: 29522843
Reply to P. Kaul et al.
Hasegawa Y, Tsukahara K, Yoshimoto S, Miura K, Yokoyama J, Hirano S, Uemura H, Sugasawa M, Yoshizaki T, Homma A, Chikamatsu K, Suzuki M, Shiotani A, Matsuzuka T, Kohno N, Miyazaki M, Oze I, Matsuo K, Kosuda S, Yatabe Y. Hasegawa Y, et al. Among authors: yoshizaki t. J Clin Oncol. 2021 Nov 1;39(31):3518-3519. doi: 10.1200/JCO.21.01554. Epub 2021 Sep 10. J Clin Oncol. 2021. PMID: 34506232 No abstract available.
In-scalp incision technique for cochlear implantation.
Sugimoto H, Hatano M, Yoshizaki T. Sugimoto H, et al. Among authors: yoshizaki t. Clin Otolaryngol. 2021 Jan;46(1):101-105. doi: 10.1111/coa.13630. Epub 2020 Nov 3. Clin Otolaryngol. 2021. PMID: 32790042 No abstract available.
Olfactory dysfunction in LATY136F knock-in mice.
Kaneda M, Yagi-Nakanishi S, Ozaki F, Kondo S, Mizuguchi K, Kawano M, Malissen M, Malissen B, Yamada K, Yoshizaki T. Kaneda M, et al. Among authors: yoshizaki t. Auris Nasus Larynx. 2022 Apr;49(2):209-214. doi: 10.1016/j.anl.2021.07.009. Epub 2021 Aug 1. Auris Nasus Larynx. 2022. PMID: 34348847
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Takahashi S, Oridate N, Tanaka K, Shimizu Y, Fujimoto Y, Matsumoto K, Yokota T, Yamazaki T, Takahashi M, Ueda T, Hanai N, Yamaguchi H, Hara H, Yoshizaki T, Yasumatsu R, Nakayama M, Shiga K, Fujii T, Mitsugi K, Takahashi K, Nohata N, Gumuscu B, Swaby RF, Tahara M. Takahashi S, et al. Among authors: yoshizaki t. Int J Clin Oncol. 2022 Dec;27(12):1805-1817. doi: 10.1007/s10147-022-02233-6. Epub 2022 Oct 20. Int J Clin Oncol. 2022. PMID: 36264378 Free PMC article. Clinical Trial.
The roles of IL-17C in T cell-dependent and -independent inflammatory diseases.
Yamaguchi S, Nambu A, Numata T, Yoshizaki T, Narushima S, Shimura E, Hiraishi Y, Arae K, Morita H, Matsumoto K, Hisatome I, Sudo K, Nakae S. Yamaguchi S, et al. Among authors: yoshizaki t. Sci Rep. 2018 Oct 24;8(1):15750. doi: 10.1038/s41598-018-34054-x. Sci Rep. 2018. PMID: 30356086 Free PMC article.
520 results